Trials / Completed
CompletedNCT01433263
Clinical Study of BYM338 for the Treatment of Unintentional Weight Loss in Patients With Cancer of the Lung or the Pancreas
A Randomized, Double-blind, Placebo-controlled Multi-center Study of BYM338 for Treatment of Cachexia in Patients With Stage IV Non-small Cell Lung Cancer or Stage III/IV Adenocarcinoma of the Pancreas
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 57 (actual)
- Sponsor
- Novartis Pharmaceuticals · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
A safety \& efficacy clinical study of the investigational medicinal product BYM338 for the treatment of unintentional weight loss in patients with cancer of the lung or the pancreas
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | BYM338 active drug | |
| DRUG | Placebo |
Timeline
- Start date
- 2011-08-01
- Primary completion
- 2014-04-01
- Completion
- 2014-04-01
- First posted
- 2011-09-13
- Last updated
- 2016-03-02
- Results posted
- 2015-05-13
Locations
10 sites across 5 countries: United States, Lithuania, Romania, Switzerland, United Kingdom
Source: ClinicalTrials.gov record NCT01433263. Inclusion in this directory is not an endorsement.